Company Encyclopedia
View More
name
Nurix Therapeutics
NRIX.US
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc.
1.946 T
NRIX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking92/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-65.35%E
    • Profit Margin-292.50%E
    • Gross Margin-990.96%E
  • Growth ScoreB
    • Revenue YoY48.32%A
    • Net Profit YoY-38.32%D
    • Total Assets YoY1.73%C
    • Net Assets YoY-1.22%D
  • Cash ScoreB
    • Cash Flow Margin-34.19%D
    • OCF YoY48.32%A
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreB
    • Gearing Ratio28.75%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Officer Ring Sells 37,600 ($641.7K) Of Nurix Therapeutics Inc [NRIX]

    Christine Ring, an officer at Nurix Therapeutics Inc, sold 37,600 shares worth $641,697 as part of a prearranged trading plan. The transaction was disclosed in a Form 4 filed with the SEC on November 24, 2025. Her ending holdings are 50,897 shares.

    Reuters·
    US
    NRIX
    +7.07%
    Reuters·
    US
    NRIX
    +7.07%

    Nurix Therapeutics Chief Legal Officer Christine Ring Reports Sale of Common Shares

    Christine Ring, Chief Legal Officer of Nurix Therapeutics Inc., reported the sale of common shares of the company. The information was published via EDGAR by Nurix Therapeutics Inc. on November 24, 2025. This brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    NRIX
    +7.07%
    Reuters·
    US
    NRIX
    +7.07%

    Artisan Partners Limited Partnership Lowers Position in Nurix Therapeutics, Inc. $NRIX

    Artisan Partners Limited Partnership reduced its stake in Nurix Therapeutics by 9.1% in Q2, owning 580,749 shares worth $6.6 million. Other institutional investors like Goldman Sachs and Sumitomo Mitsui Trust Group adjusted their positions, with some increasing their stakes. Analysts have mixed ratings on Nurix, with a consensus rating of 'Moderate Buy' and an average target price of $26.67. Nurix's stock performance shows a 52-week range of $8.18 to $23.00, with recent earnings missing estimates.

    Market Beat·
    US
    NRIX
    +7.07%
    US
    APAM
    -0.21%
    Market Beat·
    US
    NRIX
    +7.07%
    US
    APAM
    -0.21%

    Nurix Therapeutics (NRIX): Evaluating Valuation After J.P. Morgan’s New Positive Analyst Call

    Nurix Therapeutics (NRIX) has gained investor interest following a positive analyst call from J.P. Morgan's Tessa Romero. The stock has seen a 44% rise in the past month and a 51% gain over 90 days, despite a 30% decline in one-year total shareholder return. The company's price-to-sales ratio of 18.6x is significantly higher than industry averages, suggesting overvaluation. Investors are evaluating whether the stock remains undervalued or if growth expectations are already priced in. Simply Wall St provides analysis but not financial advice.

    Simplywall·
    US
    NRIX
    +7.07%
    Simplywall·
    US
    NRIX
    +7.07%

    Candriam S.C.A. Sells 326,547 Shares of Nurix Therapeutics, Inc. $NRIX

    Candriam S.C.A. reduced its stake in Nurix Therapeutics by 55.4% in Q2, selling 326,547 shares. Nurix's stock opened at $12.80, up 3.0%. Analysts have mixed ratings, with a moderate buy consensus and a price target of $26.67. Insider Gwenn Hansen sold 4,087 shares, impacting the stock position.

    Market Beat·
    US
    NRIX
    +7.07%
    Market Beat·
    US
    NRIX
    +7.07%
    © 2025 Longbridge｜Disclaimer